Chronic lymphocytic leukemia--correlation of response and survival.
Chronic lymphocytic leukemia (CLL) is considered to be an incurable hematologic malignancy using conventional therapy. Complete remissions (CR) were unusual with conventional approaches such as chlorambucil with or without prednisone or cyclophosphamide, vincristine, and prednisone (CVP). Pathologic complete remissions including negative bone marrow biopsies were seldom mentioned in the literature. Two parameter flow cytometry has demonstrated that CLL cells co-express CD5 and pan-B cell antigens such as CD19 and CD20. In addition, immunoglobulin gene rearrangement occurs predictably in B-cell CLL and can be used as a further marker of completeness of remission. The National Cancer Institute (NCI) has published criteria for complete remission which allow persistent lymphoid nodules to be present on the bone marrow biopsy and the patient can be considered in complete remission. Our group has considered these patients to have a nodular CR (Nod CR) to separate them from having a true remission on bone marrow biopsy (CR-bx). Thus bone marrow biopsy criteria, two parameter flow cytometry, and immunoglobulin gene rearrangement are now available for routine clinical application to re-define completeness of remission in CLL. With the use of fludarabine monophosphate (Fludara), complete and partial responses are obtained in 50-55% of previously treated patients with CLL and 75-80% of patients with previously untreated CLL. There was a strong correlation of probability of response with degree of previous therapy, stage of disease, age, hemoglobin level, platelet count, serum albumin and beta 2-microglobulin, and bone marrow infiltration with lymphocytes. Patients can be identified as being at high/low risk of achieving a complete or partial response.(ABSTRACT TRUNCATED AT 250 WORDS)
Keating
M J
MJ
Department of Hematology, University of Texas M.D. Anderson Cancer Center, Houston 77030.
O'Brien
S
S
Robertson
L
L
Huh
Y
Y
Kantarjian
H
H
Plunkett
W
W
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000401:mortality; D012074:Remission Induction; D015996:Survival Rate; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D014740:Vidarabine; C024352:fludarabine